Urology · Orange City, FL
NPI
1306074646
Since 2009
Specialty
Urology
Code 208800000X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
2583 S Volusia Ave Ste 300
Orange City, FL, 32763
Phone (386) 736-2121
Groups this clinician bills Medicare through
Medicare paid, 2024
$876K
21,948 services
Medicare patients, 2024
1,374
Average age 77
Drug cost, 2024
$7.8M
6,516 prescriptions
Company payments, 2025
$4,426
From 29 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Arash Rafiei Karkvand was code J0897 (injection, denosumab, 1 mg), 5,700 times for 23 patients. In total Arash Rafiei Karkvand billed 21,948 services in 100 codes, and Medicare paid $876K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-03-04.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 5,700 | 23 | $20.53 | $117K |
| J9030 Bcg live intravesical instillation, 1 mg | Office | 2,801 | 11 | $2.19 | $6,138 |
| 81001 Clinical Chemistry | Office | 942 | 617 | $3.10 | $2,924 |
| 36415 Venipuncture Blood Collection | Office | 885 | 629 | $7.01 | $6,204 |
| 51798 Ultrasound - Nonspecific | Office | 736 | 511 | $8.05 | $5,924 |
| 99214 Office E&M - Established | Office | 721 | 522 | $84.65 | $61K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 578 | 474 | $10.59 | $6,121 |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 408 | 112 | $52.19 | $21K |
| 81003 Clinical Chemistry | Office | 259 | 198 | $2.20 | $570 |
| J9217 Leuprolide acetate (for depot suspension), 7.5 mg | Office | 227 | 28 | $138.66 | $31K |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 184 | 75 | $39.94 | $7,349 |
| 96402 Chemotherapy Administration | Office | 166 | 42 | $26.14 | $4,339 |
| 52000 Cystourethroscopy | Office | 160 | 134 | $178.71 | $29K |
| 99204 Office E&M - New | Office | 127 | 127 | $101.23 | $13K |
| 51702 Other Organ Systems | Office | 119 | 43 | $48.09 | $5,723 |
By year: 2022 $211K for 7,484 services; 2023 $344K for 11,138 services; 2024 $876K for 21,948 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81001 Clinical Chemistry | 942 | 617 | $3.10 | $2,924 |
| 36415 Venipuncture Blood Collection | 885 | 629 | $7.01 | $6,204 |
| 81003 Clinical Chemistry | 259 | 198 | $2.20 | $570 |
Medicare prescription drug claims, 2024
In 2024, the drug Arash Rafiei Karkvand prescribed most often to Medicare patients was Tamsulosin Hcl, with 1,657 prescriptions and refills. In total Arash Rafiei Karkvand wrote 6,516 Medicare prescriptions that cost $7.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tamsulosin Hcl Generic | 1,657 | 4,586 | 666 | $31K |
| Finasteride Generic | 758 | 2,111 | 296 | $11K |
| Doxycycline Hyclate Generic | 477 | 481 | 393 | $2,849 |
| Orgovyx Relugolix | 309 | 309 | 51 | $791K |
| Erleada Apalutamide | 275 | 285 | 33 | $4.0M |
| Myrbetriq Mirabegron | 179 | 361 | 76 | $160K |
| Solifenacin Succinate Generic | 173 | 459 | 84 | $8,913 |
| Ciprofloxacin Hcl Generic | 165 | 167 | 135 | $932 |
| Tramadol Hcl Generic | 161 | 161 | 149 | $448 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 153 | 153 | 136 | $865 |
| Cephalexin Generic | 140 | 191 | 97 | $1,076 |
| Abiraterone Acetate Generic | 139 | 149 | 25 | $192K |
| Gemtesa Vibegron | 121 | 236 | 47 | $106K |
| Xtandi Enzalutamide | 120 | 120 | 14 | $1.5M |
| Prednisone Generic | 116 | 119 | 26 | $756 |
Brand drugs: - claims; generic drugs: 5,340 claims; opioid claims: 324.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Arash Rafiei Karkvand $4,426 ($4,426 in general payments such as food, travel and fees) from 29 companies. The largest payer was Medtronic, Inc. with $1,281.
| Company | Payments | Amount |
|---|---|---|
| Medtronic, Inc. MDT | 11 | $1,281 |
| Ferring Pharmaceuticals Inc. | 13 | $497 |
| Coloplast Corp | 4 | $452 |
| Telix Pharmaceuticals TLX | 2 | $219 |
| Procept Biorobotics Corporation PRCT | 5 | $218 |
| Janssen Biotech, Inc. JNJ | 9 | $211 |
| Dendreon Pharmaceuticals LLC | 3 | $185 |
| Tempus AI, Inc TEM | 3 | $130 |
| Novartis Pharmaceuticals Corporation NVS | 5 | $118 |
| Urogen Pharma, Inc. URGN | 3 | $113 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.